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Abstract 
Aims and Objectives 
To determine if a portable FibroScan® device can be an acceptable screening tool for chronic liver 
disease (CLD) in a community alcohol support service, through recording uptake, determining apparent 
prevalence of undiagnosed fibrosis/cirrhosis in participants and report engagement following referral to 
specialist liver services of those individuals referred because of a FibroScan® reading ≥ 7.1kilopascals 
(kPa). 
Background 
Alcohol related liver disease, including cirrhosis, is a major cause of death in the UK. Liver disease is 
silent and usually presents late. Socially deprived patients with alcohol related liver disease are a “hard 
to engage” population and at higher risk of death than less deprived. A FibroScan® device is a non-
invasive tool for measuring liver stiffness. A result of ≥7.1kPa can indicate possible CLD. 
 
Design 
Prospective observational study 
 
Method 
Individuals who self-identified as harmful drinkers were recruited. Consented individuals attended for a 
liver FibroScan®. Those with a reading ≥7.1kPa were referred to a nurse-led liver clinic for further 
investigations, results of which determined referral to a liver specialist in secondary care. Participants 
referred were monitored for compliance over a six-month period. 
                                                                                                                               
Results  
Seventy-nine consented individuals participated, an uptake of 67% of those informed of the study. Of 
the 79 scans performed, three were unreliable leaving 76 participants. After scanning, 20/76 (26%) had 
a FibroScan® ≥7.1kPa requiring referral on to the nurse led clinic. All 20 (100%) engaged in further 
assessment. Of those, 12 required onward referral to specialist services. Subsequent compliance with 
specialist services in this sample (n=12) was ≥ 90%. 
 
Conclusion  
A nurse led FibroScan® outreach clinic encourages socially deprived drinkers to engage with liver 
services.  
 
Relevance to clinical practice 
A 67% uptake suggests a nurse led FibroScan® service in a community alcohol service is acceptable. High 
engagement gives potential for early intervention and improved health outcomes. 




Liver disease, including cirrhosis, is the third commonest cause of premature death in the UK and  
mortality rates have  increased by approximately 500% in those under the age of 65 years since 1970 
(Williams et al 2014). As such, it stands as an exception to the improved prognosis of those with other 
chronic illnesses such as chronic heart disease, stroke and some cancers (Williams et al 2014). Deaths 
from chronic liver disease (CLD), including cirrhosis, increased globally between 1990 and 2013 from 1.5 
million to 2.1 million (Cowie et al 2015). Within the European Union, standardised death rates from 
chronic liver disease were 13 per 105 in 2013, compared to 16 per 105 in the UK alone (WHO 2017). 
Alcohol related liver disease (ALD) is a major contributor to morbidity and mortality in the UK. Current 
data for death rates due to alcohol in the UK, including ALD, report rates at 14 per 105 since 2012 
(ScotPHO 2017). This pattern is mirrored in Scotland, but with rates higher than in the rest of the UK. 
Death rates in men are 30 per 105 in Scotland and 18 per 105 in England and for Scottish women are 13.3 
per 105 and 9.1 per 105 in England (ONS 2017). In 2015, mortality rates from CLD in Scotland in the most 
deprived decile were six times those of the least deprived (34 v 6 per 105) and morbidity rates were five 
times higher (435 v 88 per 105) (ScotPHO 2017). These data demonstrate the impact deprivation and 
health inequality issues have on CLD. 
Cirrhosis is often asymptomatic, and, in most cases, treatable liver disease goes undiagnosed and 
untreated. This can result in most patients with liver disease presenting at an advanced stage (Williams 
et al 2014). The three main causes of cirrhosis are obesity, viral hepatitis or excess alcohol consumption 
(BASL-BSG 2009). Excessive alcohol consumption can cause inflammation of the liver and an 
accumulation of fats within the liver cells which, if persistent, can lead to fibrosis before development of 
cirrhosis through an insidious process of replacement of liver cells with connective tissue (Sargent 2009). 
Fibrosis is often a precursor to cirrhosis, if the cause of liver damage continues. Identification of fibrosis 
therefore plays an important part in the early detection of the disease process.  
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Long term complications of cirrhosis include oesophageal varices, secondary to portal hypertension; the 
most common lethal complication of cirrhosis through gastrointestinal bleeding (Garcia-Tsao et al 2007). 
Further complications include liver failure and hepatocellular carcinoma (hepatoma), a primary liver 
cancer (Muir 2015). Early diagnosis of cirrhosis triggers assessment for complications, initiation of 
regular hepatoma and variceal surveillance, treatment and lifestyle changes to prevent progression of 
the disease; thus improving survival, even in advanced cases of cirrhosis (Verrill et al 2009). Early 
identification and prevention of liver disease is also key in reducing the financial burden to the NHS, 
where the cost of alcohol related health problems alone are predicted to be around £17 billion (Lancet 
Commission 2017). 
Screening for Chronic Liver Disease 
While liver biopsy is considered the gold standard diagnostic tool for cirrhosis (Castera 2011) the 
invasive nature and risk of complications renders it unsuitable for use as a screening tool in a community 
setting.  A range of less invasive and non-invasive methods are available for the detection of fibrosis or 
cirrhosis, ranging from blood tests to more sophisticated methods including magnetic resonance 
imaging (MRI) (EASL-ALEH 2015). Of these, Liver Function Tests (LFTs) are the most commonly used 
blood tests.  Many of these tests rely on biochemical changes induced by altered liver function. In a 
large population based retrospective cohort study (n= 95,977) the link to outcomes of liver disease and 
mortality from a large database in primary care in Tayside from 1989 -2003 suggested that, while 
specificity of these tests was generally high, sensitivity was low with gamma glutamyl transferase (GGT) 
having the best sensitivity at 72% (Donnan et al 2009). In addition, interpretation of LFTs can be difficult 
and confusing for non-liver specialists.  Referral to specialist liver services often relies on the GP or 
health practitioner’s ability to interpret these results (Cook et al 2015). Due to the size and cost of MRI 
equipment this method of screening is not appropriate in a non-acute setting.  
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Cirrhosis develops because of increased fibrotic tissue and, as a result of this, liver stiffness increases 
(Muir 2015). Several liver fibrosis scoring systems have been derived, the two most commonly used 
being METAVIR (F0-F4) and Ishak (F0-F6). Although these are derived from histological features on liver 
biopsies, the following terminology is widely used in non-invasive assessment techniques: F0 = no 
fibrosis; F1 = mild fibrosis; F2 = moderate fibrosis; F3 = severe fibrosis; F4 = cirrhosis. Non-invasive 
assessment of liver fibrosis can use blood tests or imaging techniques (Sargent 2009). Hyaluronic acid 
(HA) is one such blood test used in specialist services but is non-specific for the liver and can be raised in 
cases of arthritis (Adams 2011). 
Transient Elastography (TE), measured by a FibroScan® device is a non-invasive imaging test of fibrosis 
which is currently used in specialist centres as a screening and diagnostic tool for liver disease.  It 
measures liver stiffness in kilopascals (kPa), using the propagation of an elastic shear wave through liver 
tissue from an ultrasound transducer probe. This is a quick, painless, non-invasive assessment for 
cirrhosis using liver stiffness measurements (LSM) which gives an instant result.  TE has been validated 
as a reliable marker for fibrosis and cirrhosis in a heavy alcohol using group (Nguyen-Khac et al 2008, 
Thiele et al 2015). The FibroScan® device is available in portable form which, if used in a community 
setting, could reduce the need for attendance at specialist centres. The portable FibroScan® has been 
demonstrated to elicit equivalent readings when compared to a static FibroScan® (Parra-Ruiz et al 2014). 
Nurses trained in the use of FibroScan® have been shown, through research, to elicit comparable 
readings to their medical colleagues (McCorry et al 2012). This evidence suggests that FibroScan® could 
be used by nurses in the community.  
A subject which continues to foster debate in the literature is the agreement on the lower cut off 
measurement for FibroScan® readings which corresponds to any degree of hepatic fibrosis (F1-F4). This 
lower cut off measurement determines whether someone is discharged or requires further clinical 
investigation. Recent studies have used 8.0 kPa as the lower measurement (Harmen et al 2015, Roulot 
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et al 2013); however the threshold can vary depending on the cause of fibrosis. A small study comparing 
FibroScan® with liver biopsy in alcohol related liver disease suggested a lower cut-off for severe fibrosis 
(F3) of 12.9kPa (Nahon et al 2008). When offering this intervention in a community alcohol support 
setting, as the sole initial screening test, without the back up of additional tests for those on or below 
the low cut off, it was considered best to abide by the lower cut off for any degree of liver fibrosis (F1-
F4), of 7.1 kPa as suggested by Castera, Forns and Alberti (2008) to increase the likelihood that fibrosis is 
detected whatever the cause whether it be alcohol, obesity, viral hepatitis or other, less common, 
causes. Setting a lower cut off should also reduce the risk of non-detection in borderline cases. Setting 
this cut off also allows for the opportunity to add to the literature for detection of fibrosis with readings 
≥7.1kPa and < 8.0 kPa.  
Research context 
The World Health Organisation (WHO) (2011) pledged to address health inequalities through developing 
strategies to promote effective partnerships with health and other sectors in achieving health through 
policies and actions on social determinants of health, specifically targeting vulnerable and high risk 
groups. In Scotland, the Public Bodies (Joint Working) Scotland Act (Scottish Government 2014) 
introduced a statutory duty for NHS Boards and Councils to integrate planning and delivery of health 
and social care services, strengthening the Scottish Government’s commitment to community-based 
anticipatory care (Audit Scotland 2015). This care is to be provided jointly between the NHS, statutory 
and non-statutory social care providers with the aim of reducing the number of patients with long term 
conditions being admitted to acute services (Audit Scotland 2015).  
Nurse led clinics aim to provide, facilitate and expand access to quality care to an often vulnerable 
population who may not otherwise access care in mainstream services (Kleinpell et al 2014). Feedback 
from users of such services is generally very positive, with patients valuing the improved access to care 
and their increased opportunity to become partners in managing their condition through the person-
 Karen Matthews, Alastair MacGilchrist, Margaret Coulter-Smith, Jacklyn Jones, Roseanne 
Cetnarskyj 
 
centred approach. They value the time afforded to them during their consultation with the nurse, where 
an open, non-judgmental dialogue prioritises the patient’s story, a characteristic of advanced practice 
(Kucera, Higgins and McMillan 2010).  
As over 90% of cases of hepatitis C have been acquired through injecting drug use (Scottish Government 
2015),  nurse led services were set up in both community and acute settings in Scotland to increase the 
screening for and treatment of hepatitis C, as supported by the Sexual Health and BBV Framework 
(Scottish Government 2015).  
Those infected with hepatitis C have a defined diagnosis elicited through a specific screening blood test, 
followed up by a confirmatory blood test which amplifies the hepatitis C virus through polymerase chain 
reaction (Sargent 2009). As screening tests for CLD with blood tests can be unreliable (Muir 2015) and 
would not be wholly relied upon in its diagnosis, those with alcohol related liver disease do not benefit 
from the same quality of screening. They may however benefit from nurse-led services where screening 
for liver disease is offered. At time of review and to date, there is no full text published literature on 
screening for liver disease with a FibroScan® device in a population of high alcohol consumption utilising 
community alcohol support services.  
Foucher et al (2009), Marshall et al (2015) and Thurnheer et al (2015) conducted prospective cohort 
studies which targeted People Who Inject Drugs (PWIDs), with a high risk of hepatitis C, to determine 
the viability and acceptability of screening for liver disease with a FibroScan® device in community 
settings, including drug support centres in France (Foucher) and Australia (Marshall and Thurnheer). All 
studies found screening with FibroScan® to be acceptable in reasonably large cohorts of 298 (Foucher et 
al 2009), 235 (Marshall et al 2015) and 623 (Thurnheer et al 2015). Foucher et al (2009) demonstrated 
an increased uptake in engagement of hepatitis C treatment services for the duration of the study and 
concluded that uptake of screening and engagement with treatment for hepatitis C was a direct result of 
having a FibroScan®. However, it is unclear how participants were recruited other than that they were 
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“offered” a FibroScan®. If they relied upon the clinicians directly delivering the services or those running 
the study to recruit participants it is possible that the motivation of the participants could be influenced 
by the motivation of the recruiting clinicians to engage this group over the study period and this may, 
subsequently, have influenced the outcome; this needs further clarification. Marshall et al (2015) 
offered participants a voucher to the value of $20 for their participation which may have influenced 
their choice in taking part, and possibly their attitude towards the acceptability of the FibroScan®.  
Thurnheer et al (2015) also sought to compare disease prevalence between tertiary clinics, community 
clinics, clinics for PWIDs and regional clinics. Results showed that FibroScan® was feasible as a screening 
tool within a community setting and that a higher level of more advanced liver disease was found in 
what were described as “regional clinics”; a term not clarified further. Hepatitis C was a known factor 
with this group, however while alcohol use was documented, it was not quantified. While higher 
incidence of disease within the regional clinics may suggest lower socioeconomic status with poor access 
to tertiary care this is not stated and cannot be assumed.  In addition, the cause of liver disease varied 
between the cohorts with those from community clinics more likely to be infected with hepatitis B from 
birth and of different ethnic origin with different lifestyle factors and therefore not directly comparable. 
Nonetheless, of interest is the higher prevalence of disease out with the tertiary setting suggesting acute 
services may not be reaching those at most risk.  
In their prospective cross sectional study in two primary care practices in Nottingham (n=504) Harman 
et al (2015) targeted those at high risk of liver disease through hazardous alcohol use, type 2 diabetes or 
a persistently elevated liver function enzyme (ALT).  They demonstrated the inadequacy of screening 
using LFTs alone with 26% of participants eliciting an elevated FibroScan® result (n=98) while 71/98 
(72%) of these participants, had normal LFTs. The lower threshold for the FibroScan® result was 8.0kPa in 
this study. In addition, 11 patients were identified with cirrhosis which had not been previously 
diagnosed. While FibroScan® was not the initial screening tool in this study; it further demonstrates the 
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current inadequacy of screening using LFTs alone. In addition, while they targeted those at high risk of 
liver disease, with a yield of 26% with raised liver stiffness measurements (LSM), Roulot et al (2013) 
offered screening using a FibroScan® device to all patients over the age of 45 years old attending a social 
medical centre in France for a routine medical check up. The prevalence of elevated LSM (with ≥ 8.0kPa 
cut off) was 7% in this large self-selected sample (n=1190). This suggests that offering targeted screening 
to higher risk groups could be more efficient in unearthing undiagnosed liver disease. Although both 
these studies were carried out in a primary care setting, neither study focused on the health inequalities 
aspect of liver disease. 
Fabrellas et al (2013) sought to determine the feasibility of a nurse led screening service for CLD using a 
FibroScan® device in a primary care nurse consultancy in Spain. Participants were randomly chosen from 
the health registry and asked to participate by telephone. With a lower cut off threshold of ≥ 6.8kPa, 
and in a large sample (n=502) they concluded that such a service was feasible with a prevalence of 5.7% 
of participants with elevated liver stiffness, suggestive of fibrosis in keeping with the lower prevalence 
found in Roulot et al (2013) as compared to Harman et al (2015) discussed earlier; further 
demonstrating that targeting high risk groups for screening is more efficient. While the nurse led aspect 
of this study is of interest it was conducted in a non UK primary care setting; In addition the participants 
were randomly selected, rather than targeted according to behaviour that may predispose them to liver 
disease.  
While the studies reviewed suggest good acceptability of FibroScan®, questions remain, in some, 
regarding the possible influence of the motivation of those recruiting and the provision of a financial 
incentive on the success of their recruitment strategies. This, therefore, influenced the choice of 
recruitment strategy in this study; where the researcher was not actively involved in recruitment of 
potential participants. Reviewing the literature highlighted the inadequacy of serum markers in 
screening for liver disease and the higher prevalence of disease out with the acute setting. It also 
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highlighted that targeting a high risk group is more efficient; an important consideration for cost 
effectiveness and another which influenced this study design. Finally, while one study suggests that a 
nurse led screening service with a FibroScan® device is feasible, this was conducted in a non UK primary 
care setting.  
This review suggests nurse led clinics are acceptable to a variety of cohorts in a variety of settings. It also 
suggests that, with training, nurses are competent to deliver a service using a FibroScan® device. 
However, no studies directly investigated a nurse led FibroScan® service within the community alcohol 
setting where individuals present themselves for support.  
Aims and objectives  
 
The main aim of this pilot study was to determine the acceptability of a service providing screening for 
CLD, with a portable FibroScan® device, to a group concerned about the health of their liver due to 
elevated levels of alcohol consumption.  
Subsequent aims were to: 
1. Recorded the uptake of a FibroScan® in individuals accessing one community alcohol support 
service. 
2. Determine the prevalence of undiagnosed CLD in a self-selected, convenience sample of 
individuals accessing one community alcohol support service 
3. Reported attendance at 6 months following referral to Royal Infirmary of Edinburgh (RIE) 
specialist liver services, of those participants referred with a FibroScan® reading ≥7.1kPa. 
 
Ethics  
Ethical approval was gained from the South East Scotland Research and Ethics Committee (reference 
14/SS/1021), NHS Lothian research & development department and Edinburgh Napier University ethics 
committee. 





This was a prospective quantitative observational study. The study was active over the twelve month 
period from November2014 until the end of October 2015 with screening with FibroScan® offered 
during the first six months until April 2015; thereafter engagement with services of those requiring 
onward referral was monitored. 
Sample  
The sample was a convenience sample in one community alcohol support setting in Edinburgh.  This 
recovery centre has a catchment area which includes an area of deprivation in Edinburgh (SIMD 2017); 
therefore, those at most risk through their liver disease could be targeted (Williams et al 2014). 
As this study evaluated the acceptability of the cirrhosis screening intervention in this setting, no specific 
sample size was determined in advance. The sample size was limited to the number of individuals 
dropping in to the research clinics in a 24 week period after reading the participant information pack 
(PIP).  
Inclusion criteria included individuals over age 16, with the ability to provide informed consent who 
were attending either the triage facility for assessment of their support needs, or who were currently 
undergoing alcohol support in the centre. Exclusion criteria included the possibility of or known 
pregnancy, known to have a pacemaker, ascites, an open wound close to right 8th-10th intercostal 
margins, known cirrhosis and no alcohol history (EASL-ALEH 2015 2015). 
During the recruitment period 118 participant information packs were requested. Of these, 79 service 
users presented themselves for the study and subsequently provided consent, representing an uptake of 
67% of those who requested information. 
 




The study was advertised on a rolling TV screen in the reception area, posters in reception and all 
consultation rooms. Potential participants could then volunteer. The advertising literature was designed 
to demonstrate that participants were not required to undress, merely that the upper left quadrant of 
the abdomen was exposed for access of the FibroScan® probe, in case this assumption was a barrier to 
participation.  
PIPs were numbered and available in the reception area of the service and any staff member could 
distribute them. To assess uptake, the number of packs issued was recorded to allow response rate to 
be calculated.  The format of writing in these packs was informed by guidelines from NHS Scotland 
(2014) information aimed at the general public i.e. the level was pitched at a reading age of seven years 
and for ease of accessibility, Arial font size 11 was used. Staff checked that individuals taking a PIP were 
given the opportunity to have the information read to them on the premises. If an individual wished to 
take part in the study, they could return to a research clinic on the same premises at their convenience 
on a Tuesday or Thursday between 11-2pm. This enabled potential participants to attend on an empty 
stomach to enhance the quality of the scan (Lemoine et al 2014); a full stomach did not exclude 
participation in the study, as is current practice in other specialist liver services.  
Following discussion of the purpose of the study and an opportunity to ask questions, written consent 
was taken. Part of this consent requested to share information with the participant’s GP and other 
health professionals, as appropriate. 
Data Collection 
 A focused medical and lifestyle history (Snadden et al 2013) was taken by the hepatology nurse 
practitioner and principal investigator (KM) using a data collection tool specifically designed for this 
study (Appendix 1). Development of this tool was adapted from by the four domains of the tool 
developed by Carneiro et al (2014) i.e. Identification, Clinical Data, Physical Exam and Interview, in line 
with Gordon’s Functional Health Pattern taxonomy (Gordon 1994).  This data collected were weight, 
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height, alcohol, medical, smoking and family history, current medication and possible viral hepatitis 
risks.  Each participant had a FibroScan® screen on day of consent. For the FibroScan®, participants were 
asked to lie on a couch with their upper left quadrant exposed. The FibroScan® probe was placed 
between the 8th and 10th intercostal margin in line with operator guidelines (EASL-ALEH 2015) and, to 
improve access to the liver through opening the intercostal space, their right arm placed behind their 
head, if possible. Prior to the scan, the participant was informed they would be given an immediate 
result at time of screening and their choices for follow up would be discussed after result.  
A lower cut off measurement of 7.1kPa for referral to services was used in the study and aims to reduce 
the risk of non-detection in borderline cases, as discussed earlier. In the event of being unable to elicit a 
FibroScan® reading the participant’s GP was informed and invited to refer participants to the liver unit at 
the RIE for further assessment, should they have any concerns regarding their liver health.  
The portable FibroScan® device could not support an XL probe, resulting in an increased likelihood that 
readings from participants with a BMI >30kg/m2 were unreliable with the medium probe (de Ledinghen 
2012). Therefore the participant’s BMI was calculated from recording of weight and height. BMI result 
could enable a discussion regarding the liver health implications of a raised BMI and discussion from a 
health promotion aspect.  
Data analysis  
These data were coded using a codebook developed for this study using descriptive statistics within the 
“Statistical Package for Social Sciences” (SPSS) version 21.Demographic data was reported on the initial 
79 participants while subsequent data analysis of FibroScan® results and engagement of those requiring 
onward referral was undertaken on the 76 participants in whom reliable readings were obtained. 





Follow up based on FibroScan®   result  
For those participants who showed no signs of fibrosis or cirrhosis from their scan (≤ 7.0kPa), lifestyle 
advice was reinforced through literature on the effects of alcohol on the liver offered at the research 
appointment (Drinkaware 2013).  
Any participants with a FibroScan® reading ≥ 7.1kPa were offered an appointment to attend a NHS nurse 
led liver clinic within the same community service, on another day. The appointment date and time 
were given on the day of the FibroScan®. A reminder telephone call for the clinic appointment was also 
offered, in line with recommendations for improving engagement in harder to reach and engage groups 
(Watt 2013).   In the event of a participant having a reading ≤ 7.0kPa but showing possible signs or 
symptoms of CLD, such as current abdominal swelling, an appointment for follow up was also offered 
(Muir 2015). No participants, with a FibroScan® ≤ 7.0kPa presented with current symptoms of concern. 
At the appointment in the NHS nurse led liver clinic, blood was taken for a full liver profile, including 
platelets, hyaluronic acid and the liver enzymes alanine aminotransferase (ALT), aspartate 
aminotransferase (AST). To determine the degree of CLD those with a FibroScan® result ≥ 8.0kPa were 
referred for an ultrasound and clinical evaluation by a consultant Hepatologist or senior registrar within 
the Hepatology team. The blood results of participants with a FibroScan® result ≥7.1kPa and < 8.0kPa 
were discussed with a consultant Hepatologist, in order to decide whether further investigations and 
medical assessment were required. Liver biopsy was not required to determine the degree of CLD and 
no biopsies were taken in the study period. Regardless of the FibroScan®   result and if consent was 
provided, the GP of each participant was informed of the participant’s recruitment to study, result and 
follow-up if required.  
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All onward referral to specialist liver services and adherence to surveillance was monitored through 
checking participants’ appointment details on Trak (online tracking system used by NHS Lothian for 
booking patient appointments and recording attendance) for the duration of the study. 
Results 
Uptake of FibroScan® 
 
A total of 79 consented participants took part in the study.  A valid FibroScan® reading could not be 
obtained in three participants; all of whom had a BMI >30kg/m2.  All results presented relate to the 76 
participants with a valid FibroScan® reading. Table 1 provides demographics and key information elicited 
from the data collection tool created for this study  
Prevalence of undiagnosed cirrhosis 
Of the 76 participants, 56 (74%) elicited a FibroScan® reading of ≤ 7.0kPa, indicating no significant fibrosis 
and requiring no onward referral for further investigations. 
Of those requiring blood tests, 19/20 (95%) attended the nurse-led clinic for a full liver blood profile, 
with one participant failing to attend either of the two initial appointments at the nurse-led clinic but 
attending their GP for baseline liver bloods and thereafter the nurse-led service for further assessment 
bloods. 
Following analysis of the blood results taken at the nurse-led liver outreach clinic, none of the eight 
participants with a reading ≥7.1kPa and < 8.0kPa required onward referral for medical assessment. Of 
the remaining 12 participants seven (9%) had a reading ≥8.0kPa and < 12.5kPa indicating possible 
significant fibrosis and five (7%) had readings ≥ 12.5kPa indicating possible cirrhosis. 
On completion of the study the diagnostic outcomes (Table 2) were monitored for the 20 participants 
requiring referral to the nurse-led clinic and subsequent onward referral to specialist liver services. 
Within this group six (8%) were diagnosed with definite cirrhosis. One participant was discharged back 
to their GP following a period of alcohol reduction over a six-month follow up period. One participant 
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did not engage with their medical assessment and therefore never received a definite diagnosis. The 
remaining four (5%) were diagnosed with fibrosis and remain in follow up with specialist services. 
Engagement of participants requiring onward referral 
Of the 20 participants referred to the nurse-led service clinic within the alcohol service, 19 attended. Of 
the 12 patients expected to attend the RIE for medical assessment, 11 did so and of 10 patients 
expected to attend for six monthly follow up, nine did so. All 12 patients referred for abdominal 
ultrasound attended.  This is illustrated in Table 3. 
Discussion 
Uptake of routine health screening is low in areas of deprivation (Watt 2013), suggesting low self- 
efficacy, i.e. the confidence in one’s ability to exert control over their behaviour (Bandura 1997). This 
could be attributed to low confidence, poor literacy and financial difficulties which make negotiation 
through the process of health care delivery and travel to appointments difficult (Watt 2013). Therefore, 
an uptake of 67% in this screening study for those who received information, suggests that this 
intervention is acceptable to prospective participants in this setting. In addition, this appears to 
demonstrate a level of self-efficacy in this cohort, as suggested by their current engagement with 
alcohol support services. According to the Health Belief Model (HBM) perceived susceptibility to disease 
influences health behaviour (Sharma 2011) and may be another factor in the level of uptake in this 
cohort who, by their engagement with alcohol support are likely to be aware of the effects of alcohol on 
the health of the liver, through access to health promotion materials and consultations with support 
staff at community alcohol support service. The Theory of Planned Behaviour suggests that intention 
and self-efficacy are the best predictors of behaviour change in addition to other external control factors 
i.e. barriers or facilitators to change (Marks et al 2015). This is a self selected group who, through their 
attendance with the alcohol service, demonstrated a level of self-efficacy and motivation to change their 
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behaviour in a setting where specialised support is available and, in this respect this screening 
intervention appears to be in the right place at the right time. 
As participants were recruited through a “drop in” system, it is beyond the scope of this study to 
determine the number of potential participants who did not request research information, and their 
reasons for this, and is acknowledged as a limitation. The study results on acceptability are consistent 
with other studies demonstrating the acceptability of offering FibroScan® as a screening tool in 
community drug services (Foucher et al 2009, Marshall et al 2015, Thurnheer et al 2015) and would 
appear to show it could be an effective way of encouraging initial engagement with liver services.  
At a time when mortality from CLD, including cirrhosis, has increased by 500% since 1970 in the under 
65 age group (Williams et al 2014), the mean age of 46 years in this cohort of participants seems optimal 
for consideration of screening. With male mortality rates for CLD being almost twice as high as those 
reported for women (ONS 2017) the proportion of male to female attendees for 63% to 37% would 
appear to be representative of this population. Participant alcohol histories confirmed this to be a heavy 
drinking group, as targeted. Those with a FibroScan® reading ≥ 7.1kPa and < 8.0 kPa did not require 
onward referral once their blood profile was assessed by a Consultant Hepatologist (AMacG); supporting  
studies using a threshold of 8.0kPa (Harmen et al 2015 and Roulot et al 2013) and adding to the 
literature regarding the lower cut off for FibroScan® in general screening. 
Obesity is one of the most common causes of CLD through fatty infiltration of liver cells (Muir 2015). 
Levels of obesity are highest for those living in deprived areas (ScotPHO 2017), often due to poor diet 
and lack of exercise. Within this cohort the prevalence of obesity was 21.1%, while the current 
prevalence of obesity is 29% in the general population of Scotland (ScotPHO 2017). The portable 
FibroScan® device used in this study (FibroScan® 402) could not support an XL probe. While only three 
scans were unreliable, according to criteria in (Schwabl et al (2015), each of these participants had a BMI 
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higher than 30kg/m2. It would seem advisable, given the level of obesity, that an XL probe is available in 
future.  
Considering the uptake of screening by FibroScan®, Health Behaviour Theory, suggesting self-efficacy 
and high motivation in this cohort supports the encouraging engagement in specialist services for those 
requiring onward follow up. In addition, this is in line with the findings from Foucher et al (2009) who 
concluded that uptake of hepatitis C treatment in a group who previously had not engaged, was a direct 
result of having a FibroScan®. Sheron et al (2013) used a serum panel test to screen for liver disease 
conducted across nine GP surgeries (n=4630). They found that feedback about liver health may be a 
useful prompt for behaviour change, with the biggest reductions in drinking being seen in the group 
with heaviest drinking behaviour up to one year following the intervention. They conclude that 
combining a screening intervention for liver disease with ongoing support in alcohol recovery could have 
a positive impact on behaviour change. As Sheron et al (2013) recruited participants through their GP 
surgery with an invitation letter and a subsequent postal questionnaire their cohort is not directly 
comparable to that in this study. Nonetheless, in light of their findings, the early engagement with 
assessment and follow up in specialist services in this study was extremely encouraging as a possible 
predictor of health behaviour change. However, it is important to continue research beyond this study 
to determine what, if any, impact this type of intervention has on the longer term drinking behaviour of 
this or a similar cohort.  
In preparing for implementation of the study it was important to consider possible facilitators and 
barriers (Dogherty and Estabrooks 2015). The research venue consists of multiple agencies, playing an 
important role as the study hosts. As the only room suitable for carrying out a FibroScan® was the largest 
in the building and the one used for the various therapies on offer in the service, KM was concerned that 
this had the potential for conflict as the study progressed with possible competing demands for the use 
of the room. While there will be no randomised control trial following on from this study, guidance in its 
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development was sought using the MRC (2008) guidelines in developing and evaluating a complex 
intervention. Practical effectiveness, whether the intervention will work in everyday practice, is a key 
question to consider; therefore, designing the study to be as low maintenance as possible for staff at the 
venue was considered to be important to developing a sustainable service which would continue 
beyond the research phase and could be integrated into routine services offered there. Through KM’s 
attendance at staff meetings and informal discussion, in advance of the study, the venue staff were 
aware of its purpose and able to describe the intervention to service users. Feedback from staff was 
positive throughout the study, illustrating that staff thought it was a good idea. Their continued 
willingness to provide the room for screening, moving the time of some of their own activities to 
accommodate this booking combined with their continued enthusiasm in promoting the intervention 
through discussion with service users and displaying the study posters demonstrated cognitive 
participation, collective action and reflexive monitoring,  key elements identified in Normalisation 
Process Theory (NPT) where normalisation is the willingness to integrate a new intervention into 
everyday practice (May 2015). The support by venue staff in continuing the intervention beyond the 
study phase has prompted discussion with the stakeholders involved in the study to consider the 
possibility of continuing the provision of screening as a service; particularly in view of the unexpectedly 
high levels of engagement with services for those requiring onward referral in this study. This is 
currently being piloted as a service delivered by a team of specialist community nurses and is currently 
being evaluated. 
While devising and developing this study required the advanced practice skills of negotiation and 
leadership (NMC 2005), in their competency framework for working in liver disease, the RCN (2013) 
suggest that all nurses, regardless of clinical background have skills and talents to integrate liver health 
into routine clinical practice. Public Health England’s (PHE) “Make Every Contact Count” (MECC) agenda 
(PHE 2016) suggests that nurses are integral in making an impact on liver disease through discussion of 
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possible risks and lifestyle choices to improve liver health. In addition to alcohol intake, healthy eating, 
keeping to a healthy weight and being physically active are deemed to be three of the lifestyle issues 
which can make the greatest improvement to an individual’s health and, as such, are factors which 
should be included in every patient contact, according to PHE (2016). This is also in line with the Scottish 
Government’s “2020 vision” where a strong focus on prevention, anticipation and supported self-
management is recommended in order to improve the health of the nation (Scottish Government 2017) 
and the NHS Scotland Healthcare Quality Strategy (NHS Scotland 2010) which emphasises the use of the 
most appropriate interventions and supports in providing quality healthcare. This suggests, therefore, 
that in the context of an alcohol support centre and with appropriate training, nurses are well placed to 
deliver not only liver screening but more general lifestyle discussion to a group at high risk of liver and 
other chronic disease through their alcohol intake and obesity levels. 
In complex health interventions (MRC 2008) the success, or otherwise, is dependent on many factors 
and it is important to consider optimisation of the intervention,  in order to progress it to an embedded 
service or further research (Levati 2016, MRC 2008). Sermeus (2015) acknowledges that an increasing 
number of components characterising interventions leads to them being harder to implement and it is 
important, not only to establish the key components, but also the inactive components in the 
intervention. In this study, one possible key factor is the acceptability of the non-invasive, painless 
FibroScan® device which gives an immediate result; as opposed to blood tests which can be painful and 
do not elicit results immediately. In addition to this KM offered the FibroScan®  and also delivers the liver 
clinic at the community alcohol service and, in this respect, is motivated to work with harder to engage 
groups and familiar with some of the challenges posed (Watt 2013). In particular, this is reflected in the 
recruitment process where participants were not approached directly by KM as it was important that 
vulnerable, potential participants should not feel coerced into taking part. The ability of the nurse to 
engage with the participant’s own motivation in considering changing their behaviour (Lau-Walker et al 
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2016) and continuity of care offered by seeing the same nurse in the initial stages of the pathway may 
be a crucial factor in gaining the trust of participants and may also account for the level of engagement 
seen. As discussed, another key component may be the choice of venue, the influence and support of 
staff and, importantly, the self-efficacy and motivation of the self-selected cohort of participants. 
This was a fixed term study, not designed to assess whether the encouraging level of engagement 
continues and whether the lifestyle changes required for improving the participant’s liver health were 
instigated and continued over a longer period of time and this is acknowledged as a limitation. Further 
work is required in determining the key components of screening and to gain insight into its 
acceptability and reasons for the encouraging level of engagement. This may be possible through a 
qualitative study, collecting data using one to one interviews with consented participants to understand 
the participant experience. In addition, a longitudinal study, designed to monitor changes in lifestyle 
behaviour beyond the six months post screening in this study, would help to establish whether 
engagement and lifestyle changes were sustained. 
Conclusion 
This study suggests that cirrhosis screening using a portable FibroScan® device in the outreach setting of 
a community alcohol service in an area of high deprivation is acceptable both to participants and alcohol 
support staff. It can identify significant liver disease in the targeted population and results indicate a 
high level of early engagement in NHS liver services in a cohort of heavy drinkers, previously considered 
hard to engage. Nurse led screening in this setting provides an opportunity for education and discussion 
regarding lifestyle factors in liver disease with a cohort who seem motivated to improve their liver 
health. Further work is needed to optimise this intervention to understand, more fully, what are the 
essential active components necessary to replicate this outcome (Levati 2016, Sermeus 2015). 
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Relevance to Clinical Practice 
This study demonstrates that nurse led screening with a portable FibroScan® device in a community 
alcohol service assists heavy drinkers to engage in specialist liver services. This suggests it is an 
acceptable service development for participants, enabling early diagnosis of liver disease. As such, it is 
an intervention with the potential to be integrated into the practice of nurses working with this 
population if they receive the appropriate education, preparation and induction in its application; 
moving towards improving liver health of people in a high risk group with subsequent reduced health 
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Female (n=29) Male (n=50) Total cohort (n=79) 
Mean age in years 46 (SD=11yrs) 46 (SD=8yrs) 46 (SD=9yrs) 
Currently receiving 
alcohol support at 
the community 
service 
24(83% of female cohort) 45 (90% of male cohort) 69 (87% of total cohort) 
Attending triage 
facility – first step 
in accessing 
support 
5 (17%) 5 (10%) 10 (13%) 
Previous detox 
from alcohol 
20 (69%) 35 (70%) 55 (70%) 
Pattern of drinking Daily 22 (76%) Daily 37 (74%) Daily 59 (75%) 
Binge 4 (14%) Binge 13 (26%) Binge 17 (22%) 
Intermittent 3 (10%) Intermittent 0 Intermittent 3 (4%) 
Levels of drinking in 
units per week 
(recommended limits 14 
units for female and 21 
units for male at time of 
study)  
1-100  10 1-100 14 1-100 24 
101-200  11 101-200 21 101-200 32 
201-300  5 201-300 8 201-300 13 
301-400 1 301-400 4 301-400 5 
401-500 1 401-500 0 401-500 1 
501-600 0 501-600 1 501-600 1 




length of drinking 
in years  
10 (7,20)  15 (5,20) 12 (6,20) 
Possible symptoms 
of CLD 
6 (21%) 7 (14%) 13 (16%) 
Reported risks of 
BBVs   
12 (41%) 35 (70%) 57 (72%) 
Mean BMI of 
cohort in kg/m2 
26.5 (SD=5.6) 26.6 (SD=5.2) 26.5 (SD=5.3) 
Prevalence of 
cohort obesity  
(≥ 30kg/m2) 
8 (28%) 9 (18%) 17 (22%) 
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Table 2: Diagnostic Outcomes following FibroScan® full liver blood profile & specialist liver service appointment 
  
Diagnostic Outcomes 































































Table3: Engagement of Participants in FibroScan® Requiring Onward Referral to Specialist Services 
 
Engagement of those 
requiring onward 
referral 
Expected number Number attended Percentage 
 
Attended nurse 
appointment at the 
Venue 
20 19 95% 
Attended first medical 
appointment at RIE 
12 11 92% 
Attended six month 
follow up 
10 9 90% 
Attended USS/CT/MRI 12 12 100% 
